Backing up the European approval of Humira (adalimumab) with more data, Abbott spinout AbbVie for the first time offered long-term, patient-reported health outcomes data from the Phase III IMAgINE-1 trial in young people with Crohn's disease, along with favorable results of a caregiver survey.